The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals
The Federal Trade Commission's settlement agreement allowing Amgen's acquisition of Horizon Therapeutics to proceed may signal that other large pharmaceutical industry deals will face less regulatory scrutiny, potentially impacting pending acquisitions like Pfizer's purchase of Seagen.